Abstract:Background: Accumulating evidence indicates that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) lower glucose mainly by enhancing glucose-dependent stimulation of insulin secretion. However, the underlying mechanisms remain to be further investigated. Methods: C57BL6/J mice fed with 12-week high-fat diet (HFD) were treated with exenatide (a GLP-1 RA, 24nmol/kg/d), GW501516 (a PPARΔ agonist, 2mg/kg/d) or saline injection as control for 8 weeks. Phenotypic evaluations were performed during and after the intervention. Tolerance tests and insulin measurement were performed after 8-week treatment. The mouse pancreatic β-cell line MIN6 was used as an in vitro model. The MIN6 cells were treated with GW501516 (10uM), exendin-4 (a GLP-1 RA, 20nM) combined with GSK0660 (a PPARΔ antagonist, 10uM) or not. Furthermore, mediums containing various concentrations of exendin-4 (1, 20 and 100 nM) or GW501516 (0.1, 1, 10 and 100uM) were applied. And the cells were incubated for 24 hours. PPARΔ and uncoupling protein-2 (UCP-2) protein expression were detected. Results: Compared with the control group, exenatide and GW501516 treatment led to decreased body weight and improved insulin sensitivity in HFD mice. The mice in control group had higher serum insulin levels during the tolerant tests, but their early-phase insulin secretion was lacking, indicating the impaired insulin sensitivity and β-cell function. Both exenatide and GW501516 decreased the serum insulin levels in the HFD mice. Importantly, the lacking early-phase insulin secretion were recovered by both exenatide and GW501516. The protein expression of PPAR Δ was promoted while that of UCP-2 was decreased by exendin-4 in a dose-dependent manner. Similar results were found in cells treated with GW501516. However, these salient effects were partly reversed by GSK0660. Conclusions: The effect of the GLP-1 RA exenatide on promoting β-cell function might be related to the activation of PPARΔ/UCP-2 pathway. Disclosure Y. Su: None. W. Xu: None. B. Lin: None. Z. Liu: None. Y. Chen: None. Z. Ye: None. L. Gan: None. B. Yao: None. Funding National Natural Science Foundation of China (81770821 to W.X.)

Effects of Exenatide Therapy on Insulin Resistance in the Skeletal Muscles of High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats.

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and During Hyperinsulinemic-Euglycemic Clamp.

Effects of Exenatide on Lipid Metabolism of Adipose Tissue in Diabetic Rats

1938-P: GLP-1 Receptor Agonist Ameliorates Intramyocellular Lipid Deposition Without Weight Loss by Activating AMPK

Exenatide Prevents High-Glucose-induced Damage of Retinal Ganglion Cells Through a Mitochondrial Mechanism

Exenatide Exerts Direct Protective Effects on Endothelial Cells Through the AMPK/Akt/eNOS Pathway in a GLP-1 Receptor-Dependent Manner.

Comparing the Effects of Twice-Daily Exenatide and Insulin on Renal Function in Patients with Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Controlled Trial.

Pharmacokinetic/pharmacodynamic Studies on Exenatide in Diabetic Rats

Effects of Exendin-4 on Glucose and Lipid Metabolism in Diabetic Rats

Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice

Role of LRP5/6/GSK‐3β/β‐catenin in the differences in exenatide‐ and insulin‐promoted T2D osteogenesis and osteomodulation

Exenatide Attenuates Obesity-Induced Mitochondrial Dysfunction by Activating SIRT1 in Renal Tubular Cells

2106-P: Glucagon-Like Peptide-1 Receptor Agonist Exenatide Promotes ß-Cell Function via Activation of PPARd/UCP-2 Pathway

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy

Effect of Exendin-4 on Lipid Deposition in Skeletal Muscle of Diet-Induced Obese Mice and Its Underlying Mechanism

GLP-1 Receptor Agonist Improves Mitochondrial Energy Status and Attenuates Nephrotoxicity In Vivo and In Vitro

Exenatide Mitigates Inflammation and Hypoxia along with Improved Angiogenesis in Obese Fat Tissue.

Exenatide Activates the APPL1-AMPK-PPARα Axis to Prevent Diabetic Cardiomyocyte Apoptosis.

Exenatide Treatment Increases Serum Irisin Levels in Patients with Obesity and Newly Diagnosed Type 2 Diabetes.

Exenatide Treatment Decreases Fasting Fibroblast Growth Factor 21 Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.

Effects of Exenatide Versus Insulin Glargine on Body Composition in Overweight and Obese T2DM Patients: a Randomized Controlled Trial